15 Years of Activatable Cell-Penetrating Peptides: Making Drug Delivery Peptides Smarter and More Selective | Research

The takeaway

This review surveys 15 years of research into activatable cell-penetrating peptides (ACPPs), which are designed to deliver drugs across cell membranes only when triggered by specific conditions, solving the selectivity problem of standard cell-penetrating peptides.

15 years of ACPP research
From the first activatable cell-penetrating peptide in 2004 to multiple activation strategies including enzyme-, pH-, and light-triggered systems

What the researchers found

Since the first activatable cell-penetrating peptide was reported in 2004, multiple activation strategies have been developed to control when and where CPPs become active. These include enzyme-triggered activation (using proteases overexpressed in diseased tissue), pH-responsive activation, light-triggered activation, and other environmental triggers. The review provides a comprehensive overview of these strategies, noting that while significant progress has been made, challenges remain in achieving the specificity and efficiency needed for clinical translation.

Why it matters

One of the biggest challenges in drug delivery is getting therapeutics inside the right cells without affecting healthy tissue. Cell-penetrating peptides can solve the membrane crossing problem, but their lack of selectivity has held back clinical applications. ACPPs address this fundamental limitation by adding an 'on/off switch' that activates only under disease-specific conditions. This could be transformative for targeted cancer therapy, gene therapy, and delivery of biologics that cannot cross cell membranes on their own.

How the study worked

This is a narrative review article that surveys the published literature on activatable cell-penetrating peptides from 2004 to 2020. The authors categorize and compare the different ACPP strategies, discussing the mechanisms, experimental evidence, advantages, and limitations of each approach.

What this study cannot tell us

As a review article, this paper synthesizes existing research rather than presenting new experimental data. The abstract does not detail specific quantitative comparisons between ACPP strategies. The review covers literature through 2020, so developments in the past several years are not included. Many of the ACPP strategies reviewed remain in early preclinical stages.

How to read the evidence

This is a review article synthesizing 15 years of published research. It does not present new experimental data but provides a comprehensive overview of the field. Review articles are valuable for understanding the state of knowledge but represent secondary rather than primary evidence.

When this study was published

Published in 2020 and covering research from 2004-2020. While the core principles remain relevant, the ACPP field has continued to advance since publication, so some newer developments may not be covered.

The bigger picture

Activatable cell-penetrating peptides represent a convergence of peptide science, drug delivery, and precision medicine. As biologics (large molecule drugs, gene therapies, RNA therapeutics) become increasingly important, the need for smart delivery systems that can selectively penetrate target cells grows. ACPPs are part of a broader push toward stimuli-responsive drug delivery platforms that could dramatically improve the therapeutic index of many treatments.

Questions still open

Which ACPP activation strategy has come closest to clinical translation, and what are the remaining barriers?
Can multiple activation triggers be combined to create even more selective cell-penetrating peptides?
How do ACPPs compare to other targeted delivery approaches like antibody-drug conjugates or lipid nanoparticles in terms of efficiency and specificity?

Common questions

What is a cell-penetrating peptide and why can't it be used as-is for drug delivery?

Cell-penetrating peptides are short amino acid sequences (typically 5-30 residues) that can cross cell membranes and carry cargo like drugs or genetic material inside cells. The problem is they penetrate all cells equally — healthy and diseased — which means they lack the targeting specificity needed for safe, effective drug delivery.

How do activatable cell-penetrating peptides solve the specificity problem?

ACPPs are engineered with a built-in 'off switch' that keeps them inactive until they encounter a specific trigger found at the disease site. For example, an ACPP might only activate when it encounters enzymes overexpressed by tumor cells, acidic pH in tumor environments, or external light directed at the target tissue. This means the peptide only delivers its drug cargo where it's needed.

Read the original research

Activatable cell-penetrating peptides: 15 years of research.

RSC chemical biology, 1(4), 192-203

View on PubMed ↗Publisher’s paper ↗

Citation

de Jong, Heleen; Bonger, Kimberly M; Löwik, Dennis W P M. (2020). Activatable cell-penetrating peptides: 15 years of research.. RSC chemical biology, 1(4), 192-203. https://doi.org/10.1039/d0cb00114g